The management of hematologic malignancies during the COVID-19 pandemic

Area of Science:

• Hematology
• Oncology
• Infectious Diseases
• Public Health

Background:

• Patients with hematological malignancies exhibit a more severe clinical course and higher mortality from COVID-19 compared to solid tumor patients and non-cancer individuals.
• The COVID-19 pandemic presents significant challenges in diagnosing and treating hemato-oncology patients effectively and promptly.
• There is an urgent need to enhance the management strategies for hematological malignancy patients during the pandemic.

Purpose of the Study:

• To review current data on the incidence and clinical course of COVID-19 in patients with hematological malignancies.
• To synthesize expert recommendations for managing these vulnerable patients during the pandemic.
• To highlight the importance of prompt diagnosis and effective treatment while minimizing SARS-CoV-2 infection risk.

Main Methods:

• A literature review of the MEDLINE database via PubMed was conducted.
• Searched for publications from December 2019 to September 2020 using terms like SARS-CoV-2, COVID-19, hematological malignancies, leukemia, lymphoma, and multiple myeloma.
• Reviewed recommendations and expert opinions from major oncology organizations (ASH, ASCO, ESMO, NCCN).

Main Results:

• Hematological malignancy patients experience worse COVID-19 outcomes.
• Expert recommendations focus on improving diagnosis, treatment, and infection prevention for these patients.
• Vaccination against influenza and pneumococcus is advised for all cancer patients.

Conclusions:

• The COVID-19 pandemic necessitates improved management protocols for hematological malignancy patients.
• Prompt diagnosis, effective treatment, and infection risk minimization are crucial.
• Adherence to expert-driven recommendations and vaccinations can improve patient outcomes.